Zusammenfassung
Subkutane Apomorphininjektionen sind eine wertvolle und effektive Therapie für Parkinson-Patienten mit wiederholten „Off”-Phasen trotz optimierter peroraler Therapie. Die durchschnittliche tägliche Zeit in „Off” kann damit halbiert werden, und die bestehen bleibenden „Off”-Perioden sind weniger ausgeprägt. Diese Effekte sind stabil, auch über längere Zeit, und es gibt keinen Anhalt für eine Toleranzentwicklung. Die Nebenwirkungen sind meistens gering ausgeprägt. Beste Effekte werden erreicht, wenn Apomorphin bei relativ jungen, aktiven und kognitiv gut funktionierenden Patienten eingesetzt wird. Subkutane Apomorphininjektionen verbessern nicht selten die Möglichkeit weiterzuarbeiten und ein weitgehend normales Leben zu führen. Durch diese zuverlässige Methode, schnell aus einer „Off”-Phase zu kommen, führt die Therapie zu mehr Freiheitsgefühl und Selbstvertrauen bei den Betroffenen.
Abstract
Apomorphine as subcutaneous injections offers a valuable and effective treatment alternative for Parkinson patients with oral medication-resistant „off” phases. Its efficacy is stable during long-term therapy, with no signs of patient tolerance. Adverse events are usually mild. The best results are obtained with relatively young, active, and cognitively intact patients. Intermittent s. c. apomorphine therapy can improve the patients' possibilities to continue to work and to live a normal social life, by offering increased freedom and self-confidence through a reliable, quick rescue from the disabling medication-resistant „off” phases.
Literatur
-
1
Pietz K, Hagell P, Odin P.
Subcutaneous apomorphine in late stage Parkinson's disease: A long-term follow-up.
J Neurol Neurosurg Psychiatry.
1998;
65
709-716
-
2
Hagell P, Odin P.
Apomorphine in the treatment of Parkinson's disease.
J Neurosci Nurs.
2001;
33
21-38
-
3
Poewe W, Kleedorfer B, Wagner M. et al .
Side-effects of subcutaneous apomorphine in Parkinson's disease.
Lancet.
1989;
i
1084-1085
-
4
Pollak P, Champay A S, Gaio J M. et al .
Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladie de Parkinson.
Rev Neurol (Paris).
1990;
146
116-122
-
5
Kempster P A, Iansek R, Larmour I.
Intermittent subcutaneous apomorphine injection treatment for Parkinson's disease.
Aust NZ J Med.
1991;
21
314-318
-
6
Hughes A J, Bishop S, Kleedorfer B. et al .
Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years.
Mov Disord.
1993;
8
165-170
-
7
Merello M, Leiguarda R.
Tratamiento de las fluctuationes motoras de la enfermedad de parkinson con inyecciones subcutaneas de apomorfina.
Medicina (B Aires).
1995;
55
5-10
-
8
Esteban-Munoz J, Marti M J, Marin C, Tolosa E.
Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations.
Clin Neuropharmacol.
1997;
20
245-252
-
9
Östergaard L, Werdelin L, Odin P. et al .
Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.
J Neurol Neurosurg Psychiatry.
1995;
58
681-687
-
10
Factor S A.
Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Neurology.
2004;
62
S12-S17
-
11
Dewey R B, Hutton T, LeWitt A, Factor S A.
A randomized, double-blind, placebo-controlled trial of subcutaneously injected Apomorphine for parkinsonian off-state events.
Arch Neurol.
2001;
58
1385-1392
-
12
Duby S E, Cotzias G C, Papavasiliou P S, Lawrence W H.
Injected apomorphine and orally administered levodopa in parkinsonism.
Arch Neurol.
1972;
27
474-480
-
13
Victor J FS, Pollak P, Gervason C L, Perret J.
Levodopa-induced diphasic dyskinesia improved by subcutaneous apomorphine.
Mov Disord.
1992;
7
283-284
-
14
Frankel J P, Lees A J, Kemster P A, Stern G M.
Subcutaneous apomorphine in the treatment of Parkinson's disease.
J Neurol Neurosurg Psychiatry.
1990;
53
96-101
-
15
Factor S A, Brown D L, Molho E S.
Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease.
Mov Disord.
2000;
15
167-169
-
16
Tison F, Wiart L, Guatterie M. et al .
Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Mov Disord.
1996;
11
729-732
-
17
Edwards L L, Quigley E MM, Harned R K. et al .
Defecatory function in Parkinson's disease: response to apomorphine.
Ann Neurol.
1993;
33
490-493
-
18
Christmas T J, Kempster P A, Chapple C R. et al .
Role of subcutaneous apomorphine in Parkinsonian voiding dysfunction.
Lancet.
1988;
2
1451-1453
-
19
Laar T van, Jansen E N, Essink A W, Neef C.
Intranasal apomorphine in parkinsonian on-off fluctuations.
Arch Neurol.
1992;
49
482-484
-
20
Koller W, Stacy M.
Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Neurology.
2004;
64, Suppl 4
S22-S26
-
21
Dewey Jr R B, Maraganore D M, Ahlskog J E, Matsumoto J Y.
Intranasal apomorphine rescue therapy for parkinsonian „off” periods.
Clin Neuropharmacol.
1996;
19
193-201
-
22
Kapoor R, Turjanski N, Frankel J. et al .
Intranasal apomorphine: a new treatment in Parkinson's disease.
J Neurol Neurosurg Psychiatry.
1990;
53
1015
-
23
Kleedorfer B, Turjanski N, Ryan R. et al .
Intranasal apomorphine in Parkinson's disease.
Neurology.
1991;
41
761-762
-
24
Wickremaratchi M, Hadjikoutis S, Lambert P. et al .
A tolerability study of intranasal apomorphine powder (5 mg) in subjects with Parkinson's disease and motor fluctuations over a 7-day period: a phase two study.
Mov Disord.
2002;
17, suppl 5
S103-S104
-
25
Sam E, Jeanjean A P, Maloteaux J M, Verbeke N.
Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
Eur J Drug Metab Pharmacokinet.
1995;
20
27-33
-
26
Montastruc J L, Rascol O, Senard J M. et al .
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
Clin Neuropharmacol.
1991;
14
432-437
-
27
Ondo W, Hunter C, Almaguer M. et al .
Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease.
Clin Neuropharmacol.
1999a;
22
1-4
-
28
Ondo W, Hunter C, Almaguer M, Jankovic J.
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
Mov Disord.
1999b;
14
664-668
-
29
Hughes A J, Webster R, Boningdon M. et al .
Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.
Clin Neuropharmacol.
1991;
14
556-561
Prof. Dr. med. Per Odin
Abt. Neurologie · Zentralkrankenhaus Reinkenheide
Postbrookstraße 103
27574 Bremerhaven
eMail: per.odin@klinikum-bremerhaven.de
